NCI RNS expectation22 May 2026 14:08
I asked GPT if an RNS would be expected in the scenario of negotiations collapsing. Based on feeding it the RNS of 5 months ago on 19th December.
>>>For an AIM-listed company like Fusion Antibodies plc, the key question is whether the collapse of negotiations would amount to inside information under the UK Market Abuse Regulation (MAR).
In practical terms:
If management concludes the proposed NCI extension is no longer realistically proceeding, and
that outcome would likely have a significant effect on the share price,
then they would generally be expected to announce it “as soon as possible”.
But there are a few wrinkles in the biotech labyrinth 🧪🌪️
The wording of that RNS was heavily caveated:
“no assurance that an extension… will be reached”
“timing or final terms”
“formal approval processes… likely to take several further months”
That language is deliberate legal armour plating. It tells the market:
“This is exploratory and uncertain.”
Because of that, failure to secure the deal might not automatically require an immediate standalone RNS unless:
negotiations formally terminate,
the NCI withdraws interest,
FAB internally decides the opportunity is dead,
or the board considers the market is materially misinformed without an update.
If instead discussions simply drift into silence, bureaucracy, or “still under review”, companies sometimes wait until:
interims/finals,
trading updates,
or another operational update, to mention that talks did not progress.
AIM Rule 11 and MAR focus on disclosure of price-sensitive developments, not a running commentary on every negotiation twitch.
The interesting nuance here is that the original RNS arguably raised expectations beyond a routine scientific collaboration because it mentioned:
“frontline human antibody discovery platform”
“range of targets”
“enhanced ownership”
“scale of the proposal”
That creates a stronger argument that a definitive failure could itself become material.
<<<<
Sign In
Follow the stocks
